Does losing weight seem out of reach? Consider the SURMOUNT-3 Study. The purpose of this 84-week randomized controlled trial is to compare the effect of tirzepatide to a placebo in reducing body weight. Tirzepatide is an injectable medication that is designed to help participants with weight management.
All participants will receive 12 weeks of intensive lifestyle modification (diet, exercise, and behavioral treatment). Participants who lose weight at least 5% of initial weight will be randomly assigned to one of two groups, tirzepatide or placebo, for 72 weeks. All participants will receive nutrition counseling. Visits will be held at the University of Pennsylvania.
Study drug and study procedures will be provided at no cost to you. Reimbursements for travel expenses and compensation for study inconvenience fees will be provided.
You may qualify for participation if:
You have a BMI greater than 27 kg/m²
You do not have Types 1 or 2 diabetes
You are available to come to Philadelphia for study visits
You have not lost more than 10 pounds weight loss in the past 3 months
For more information, please fill out the form below so that the study staff can contact you.
Study Identifier: 848385
Contact the research team to learn more about this study.